| Innovative Molecules–Life Sciences Partners: investment, 202106 financing round Series A totalling €20m incl lead investor LSP |
2021-06-07 |
| Innovative Molecules–SEVERAL: investment, 202106 financing round Series A €20m led by LSP |
2021-06-07 |
| Amyl Therapeutics–Huntsworth: public relations, 202106 service existent by Citigate Dewe Rogerson |
2021-06-03 |
| Amyl Therapeutics–Mérieux: investment, 202106 financing round Series A totalling €8.6m incl co-investor Mérieux Participations |
2021-06-03 |
| Amyl Therapeutics–Noshaq: investment, 202106 financing round Series A totalling €8.6m incl lead investor Noshaq |
2021-06-03 |
| Amyl Therapeutics–Sambrinvest: investment, 202106 financing round Series A totalling €8.6m incl co-investor Sambrinvest |
2021-06-03 |
| Amyl Therapeutics–SEVERAL: investment, 202106 financing round Series A €8.6m led by Noshaq |
2021-06-03 |
| Amyl Therapeutics–Wallonia (govt): grant/credit?, 202106 non-dilutive funding €9.7m from DG06 |
2021-06-03 |
| ImaginAb–Norgine: investment, 202106 financing round totalling $12.8m incl new + co-investor Norgine Ventures |
2021-06-03 |
| ImaginAb–SEVERAL: investment, 202106 financing round $12.8m co-led by existing investors Adage Capital + Cycad Group |
2021-06-03 |
| Gilde Investment–LifeSci: public relations, 202106 supply service existent LifeSci Advisors is media contact for Gilde Healthcare |
2021-06-02 |
| Origin.bio–Inventures: investment, 202105 financing round totalling $15m incl new + co-investor Inventures |
2021-05-26 |
| Ziphius Vaccines–OTHER: credit, 202105 convertible loan €5m |
2021-05-25 |
| Ziphius Vaccines–PERSON: investment, 202105 financing round Series A totalling €24.3m incl cornerstone investor Annie Vereecken |
2021-05-25 |
| Ziphius Vaccines–SEVERAL: investment, 202105 financing round Series A €24.3m incl Belgian Family Offices |
2021-05-25 |
| Numab–Forbion: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor Forbion Growth Opportunities Fund |
2021-05-20 |
| Numab–SEVERAL: investment, 202105 financing round Series C CHF100m co-led by new investors Novo Holdings + HBM Partners |
2021-05-20 |
| Hummingbird Bioscience–Droia Ventures: investment, 202105 financing round Series C totalling $125m incl new + co-investor Droia Ventures |
2021-05-18 |
| Hummingbird Bioscience–SEVERAL: investment, 202105 financing round Series C $125m led by Novo Holdings |
2021-05-18 |
| Accent Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| Arcus Biosciences–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| Aura Biosciences–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| Cyteir Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| Dutch DNA Biotech–Ginkgo Bioworks: investment, 202105– acquisition in cash + shares ANNOUNCED |
2021-05-17 |
| Highlight Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| Montis Biosciences–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| PACT Pharma–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| QurAlis–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| Volastra Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| Droia Ventures–SEVERAL: investment, 202105 final close €220m of Droia Genetic Disease Fund |
2021-05-11 |
| Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital |
2021-04-29 |
| Agendia–Inivata: cancer test, 202104– co-excl distribution rights €na for RaDaR liquid biopsy assay for breast cancer in North America + Europe |
2021-04-28 |
| Molecular Partners–SEVERAL: investment, 202104– US IPO at Nasdaq FILED |
2021-04-23 |
| Anavo Therapeutics–ABP (NL): investment, 202104 seed financing round totalling €20m incl co-lead investor Inkef Capital |
2021-04-22 |
| Anavo Therapeutics–Bioqube Ventures: investment, 202104 seed financing round totalling €20m incl co-investor Bioqube Ventures |
2021-04-22 |
| Anavo Therapeutics–MacDougall Advisors: public relations, 202104 service existent by MacDougall |
2021-04-22 |
| Anavo Therapeutics–Merck (DE): investment, 202104 seed financing round totalling €20m incl co-lead investor M Ventures |
2021-04-22 |
| Anavo Therapeutics–Otsuka: investment, 202104 seed financing round totalling €20m incl co-investor Taiho Ventures |
2021-04-22 |
| Anavo Therapeutics–SEVERAL: investment, 202104 seed financing round €20m led by M Ventures + Inkef Capital |
2021-04-22 |
| Forbion–SEVERAL: investment, 202104 additional €175m + final closing at hard cap of €360m of Forbion Growth Opportunities Fund I |
2021-04-20 |
| Forbion–Wealth Management Partners: investment, 202104 final closing at €360m of Forbion Growth Opportunities Fund I incl investor WMP |
2021-04-20 |
| Rinri Therapeutics–BioCity (GB): investment, 202104 financing round totalling £10m incl existing investor BioCity |
2021-04-20 |
| Rinri Therapeutics–SEVERAL: investment, 202104 financing round £10m from existing investors + incl convertible loan from UK Future Fund |
2021-04-20 |
| Rinri Therapeutics–UCB: investment, 202104 financing round totalling £10m incl existing investor UCB Ventures |
2021-04-20 |
| Lumicks–Farallon Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Farallon Capital |
2021-04-16 |
| Lumicks–Gilde Investment: investment, 202104 financing round Series D totalling $93m preferred shares incl existing + co investor Gilde HC |
2021-04-16 |
| Lumicks–Irving Investors: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Irving Investors |
2021-04-16 |
| Lumicks–Lauxera Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Lauxera Capital |
2021-04-16 |
| Lumicks–Parian Global Management: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Parian Global Mgt |
2021-04-16 |
| Lumicks–Pura Vida Investments: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Pura Vida |
2021-04-16 |
| Lumicks–SEVERAL: investment, 202104 financing round Series D $93m preferred shares led by Farallon Capital + Lauxera Capital |
2021-04-16 |
| Lumicks–Softbank: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Softbank Vision 2 |
2021-04-16 |
| Lumicks–T Rowe Price: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor funds managed by T Rowe Price |
2021-04-16 |
| Gyroscope Therapeutics–Forbion: investment, 202103 financing round Series C totalling $148m incl lead investor Forbion Growth I |
2021-03-26 |
| Gyroscope Therapeutics–SEVERAL: investment, 202103 financing round Series C $148m led by Forbion Growth I |
2021-03-26 |
| Leyden Laboratories–Alphabet: investment, 202103 financing round Series A totalling €40m incl lead investor GV |
2021-03-25 |
| Leyden Laboratories–Brook Byers: investment, 202103 financing round Series A totalling €40m incl co-investor Brook Byers |
2021-03-25 |
| Leyden Laboratories–Casdin Capital: investment, 202103 financing round Series A totalling €40m incl co-investor Casdin Capital |
2021-03-25 |
| Leyden Laboratories–F-Prime: investment, 202103 financing round Series A totalling €40m incl co-investor F-Prime |
2021-03-25 |
| Leyden Laboratories–LifeSci: public relations, 202103 supply service existent by LifeSci Communications |
2021-03-25 |
| Leyden Laboratories–SEVERAL: investment, 202103 financing round Series A €40m led by GV |
2021-03-25 |
| Meatable–Agronomics: investment, 202103 financing round Series A totalling $47m incl existing investor Agronomics |
2021-03-23 |
| Meatable–BlueYard Capital: investment, 202103 financing round Series A totalling $47m incl existing investor BlueYard Capital |
2021-03-23 |
| Meatable–DSM: investment, 202103 financing round Series A totalling $47m incl new investor DSM Venturing |
2021-03-23 |
| Meatable–Humboldt Fund: investment, 202103 financing round Series A totalling $47m incl existing investor Humboldt Fund |
2021-03-23 |
| Meatable–PERSON: investment, 202103 financing round Series A totalling $47m incl existing investor Taavet Hinrikus |
2021-03-23 |
| Meatable–PERSON: investment, 202103 financing round Series A totalling $47m incl new investors Rick Klausner + Jeffrey Leiden |
2021-03-23 |
| Meatable–Section 32: investment, 202103 financing round Series A totalling $47m incl new investor Section 32 |
2021-03-23 |
| Meatable–SEVERAL: investment, 202103 financing round Series A $47m from existing + new investors |
2021-03-23 |
| Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare |
2021-03-17 |
| ExeVir Bio–Noshaq: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Noshaq |
2021-03-16 |
| ExeVir Bio–Sambrinvest: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Sambrinvest |
2021-03-16 |
| ExeVir Bio–SEVERAL: investment, 202103 financing round Series A extension by €19m + closing at total of €42m |
2021-03-16 |
| ExeVir Bio–UCLouvain: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Vives IUF |
2021-03-16 |
| ExeVir Bio–Wallonia (govt): investment, 202103 financing round Series A extension totalling €19m incl new + co-investor SRIW |
2021-03-16 |
| AgomAb Therapeutics–Advent France Biotechnology: investment, 202103 financing round Series B totalling $74m incl existing + co-investor AFB |
2021-03-10 |
| AgomAb Therapeutics–Andera Partners: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Amdera Partners |
2021-03-10 |
| AgomAb Therapeutics–Boehringer: investment, 202103 financing round Series B totalling $74m incl existing + co-investor BIVF |
2021-03-10 |
| AgomAb Therapeutics–Cormorant Asset Management: investment, 202103 financing round Series B totalling $74m incl new + co-investor Cormorant |
2021-03-10 |
| AgomAb Therapeutics–Omnes Capital: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Omnes Capital |
2021-03-10 |
| AgomAb Therapeutics–Pontifax: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Pontifax |
2021-03-10 |
| AgomAb Therapeutics–Redmile Group: investment, 202103 financing round Series B totalling $74m incl new + lead investor Redmile Group |
2021-03-10 |
| AgomAb Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group |
2021-03-10 |
| AgomAb Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications |
2021-03-10 |
| AgomAb Therapeutics–V-Bio Ventures: investment, 202103 financing round Series B totalling $74m incl existing + co-investor V-Bio Ventures |
2021-03-10 |
| Diagenode–Hologic: investment, 202103 acquisition €130m of Diagenode by Hologic |
2021-03-01 |
| Oxular–Forbion: investment, 202103 financing round totalling £27m incl new + lead investor Forbion |
2021-03-01 |
| Oxular–SEVERAL: investment, 202103 financing round £27m led by Forbion |
2021-03-01 |
| Delphi Genetics–Achelous Partners: financial services, 202102 supply service M&A adviser for sale of Delphi Genetics to Catalent |
2021-02-23 |
| Delphi Genetics–Catalent: investment, 202102– acquisition 100% valuing Delphi Genetics at $55m |
2021-02-23 |
| Delphi Genetics–Osborne Clarke: legal services, 202102 supply service Osborne Clarke Brussels legal adviser to Delphi Genetics on sale Catalent |
2021-02-23 |
| Pan Cancer T–Netherlands (govt): grant, 202102 Health~Holland grant for public-private-partnership with Erasmus Medical Center |
2021-02-08 |
| Pan Cancer T–SEVERAL: investment, 202102 seed financing round from Swanbridge Capital + Van Herk Ventures |
2021-02-08 |
| Pan Cancer T–Swanbridge Capital: investment, 202102 seed financing round incl investor Swanbridge Capital |
2021-02-08 |
| Pan Cancer T–Van Herk: investment, 202102 seed financing round incl investor Van Herk Ventures |
2021-02-08 |
| Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets |
2021-02-04 |
| V-Bio Ventures–SEVERAL: investment, 202102 first closing €78m capital commitments for new V-Bio Ventures Fund 2 |
2021-02-04 |
| GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA |
2021-01-26 |
| GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences |
2021-01-26 |
| CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share |
2021-01-25 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo-2019.png){kind=logo}
Date![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
